Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect

• Main Authors: Fernanda Genre (Author), Raquel López-Mejías (Author), Javier Rueda-Gotor (Author), José A. Miranda-Filloy (Author), Begoña Ubilla (Author), Beatriz Carnero-López (Author), Natalia Palmou-Fontana (Author), Inés Gómez-Acebo (Author), Ricardo Blanco (Author), Trinitario Pina (Author), Rodrigo Ochoa (Author), Carlos González-Juanatey (Author), Javier Llorca (Author), Miguel A. González-Gay (Author)
• Format: Book
• Published: Hindawi Limited, 2014-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective. TRAIL is a potential biomarker of cardiovascular (CV) disease. Ankylosing spondylitis (AS) is a chronic inflammatory disease associated with metabolic syndrome (MeS) and accelerated atherosclerosis. We assessed whether disease activity, systemic inflammation, and MeS features were associa...